newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports First Quarter 2025 Financial Results

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC